Sells DefenCath, an antimicrobial catheter-lock solution, and medicines for serious infections and cardiovascular conditions to dialysis providers, hospitals and clinics.
10-K for FY2025, filed Mar 5, 2026CorMedix Inc. (collectively, with our wholly owned subsidiaries, referred to herein as “we,” “us,” “our” or the “Company”) is a…View ↗
On August 29, 2025, the Company acquired Melinta Therapeutics, LLC, a Delaware limited liability company (“Melinta”), which expanded the…View ↗
On November 15, 2023, we announced that the FDA approved the new drug application (“NDA”) for DefenCath, an antimicrobial catheter lock…View ↗
Product sales account for 98% of revenue; customers pay for products when they receive them.
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗$311.7M
10-K for FY2025, filed Mar 5, 2026
$311.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Sales, Net
Sold outright
10-K for FY2025, filed Mar 5, 2026 |
98% |
Product Sales, Net, FY2025
$304.3M Sources
|
Sold outright |
|
Contract revenue
|
2.4% |
Contract revenue, FY2025
$7.4M Sources
|
Sells DefenCath directly to hospitals and outpatient dialysis center operators; its product customers also include outpatient service providers and wholesale distributors.
10-K for FY2025, filed Mar 5, 2026
Yes. It kept 52 cents of every revenue dollar as net income in FY2025 and turned 55 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$14.7MView ↗
8-K, filed Nov 12, 2026
CorMedix and Heron Therapeutics, Inc. ("Heron") announced on November 9, 2026, that they have entered into a definitive asset purchase…View ↗
8-K, filed Jul 1, 2026
On June 25, 2026, the Audit Committee of the Board of Directors of CorMedix Inc. (the “Company”) approved the decision to change its…View ↗
Growing. Revenue grew 1632.5x in 4 years, from $190.9K in FY2021 to $311.7M in FY2025, about 536% a year.
Broader commercial portfolio
The older report centered on developing DefenCath and Neutrolin, including international commercialization; the latest describes U.S. DefenCath sales alongside marketed hospital- and clinic-focused infectious-disease and cardiovascular products.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 5, 2026
Expanded indication development
The older report described use of DefenCath for TPN patients as a possible future indication; the latest says a clinical study is underway for adults receiving TPN via central venous catheters.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 5, 2026We intend to pursue additional indications for DefenCath use as a CLS in populations with unmet medical needs that may also represent…View ↗
As a brand expansion opportunity, in the second quarter of 2025, we initiated a Phase 3, randomized, double-blind, adaptive, two-arm…View ↗
Loading...